Home Cart Sign in  
Chemical Structure| 1433953-83-3 Chemical Structure| 1433953-83-3

Structure of SAR131675
CAS No.: 1433953-83-3

Chemical Structure| 1433953-83-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SAR131675 is selective inhibitor of VEGFR3 with IC50 and Ki of 23 nM, 12 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SAR131675

CAS No. :1433953-83-3
Formula : C18H22N4O4
M.W : 358.39
SMILES Code : O=C1C(C(NC)=O)=C(N)N(CC)C2=NC(C#C[C@@](COC)(C)O)=CC=C21
MDL No. :MFCD23098773
InChI Key :PFMPOBVAYMTUOX-GOSISDBHSA-N
Pubchem ID :71295845

Safety of SAR131675

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of SAR131675

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR3

    VEGFR3, IC50:23 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Lymphatic Endothelial Cells (LECs) 30 nM SAR131675 significantly inhibited the proliferation, migration, and tube formation of lymphatic endothelial cells but did not completely block these processes. PMC10423168
Human dermal lymphatic endothelial cells (HDLECs) 10 nM or 100 nM 24 hours To investigate the effect of VEGFR3 inhibition on LEC-conditioned medium, results showed that SAR131675 pre-treatment significantly attenuated the promotive effects of LEC-conditioned medium on cardiomyocyte hypertrophy and proliferation. PMC9338339

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Rotator cuff injury model Oral 50 mg/kg/day Once daily for 2, 4, or 8 weeks To inhibit lymphangiogenesis and evaluate its effect on rotator cuff healing. Results showed that SAR131675 significantly inhibited lymphangiogenesis in the injured area and impeded rotator cuff healing, as evidenced by lower histological scores, bone morphometric parameters, and biomechanical properties. PMC9593253
Mice iCCA xenograft model 100 mg/kg Not specified SAR131675 significantly inhibited lymphangiogenesis in the iCCA mouse model but did not completely block it. PMC10423168
C57BL/6J mice Swimming exercise-induced physiological cardiac growth model Oral 100 mg/kg/d Once daily for 3 weeks To investigate the effect of VEGFR3 inhibition on exercise-induced cardiac growth, results showed that SAR131675 significantly attenuated exercise-induced cardiac hypertrophy and proliferation, and reduced lymphatic vessel density and LYVE-1, Podoplanin expression levels in the heart. PMC9338339
BALB/c mice 4T1 tumor model Oral 100 mg/kg once daily for 10 consecutive days To evaluate the effect of SAR131675 on tumor lymphatic vessel density in vivo, results showed that SAR131675 significantly reduced tumor lymphatic vessel density and enhanced intratumoral drug accumulation. PMC11016544

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.79mL

0.56mL

0.28mL

13.95mL

2.79mL

1.40mL

27.90mL

5.58mL

2.79mL

References

 

Historical Records

Categories